Abi-Saab Walid 4

4 · uniQure N.V. · Filed Mar 6, 2026

AI-generated summary of this filing

Updated Mar 6, 2026

uniQure (QURE) CMO Walid Abi‑Saab Receives RSUs; Sells Shares

What Happened

Walid Abi‑Saab, Chief Medical Officer of uniQure (QURE), received two grants of restricted share units (RSUs) on March 4, 2026: 41,700 RSUs (reported as an acquisition) and 67,200 RSUs (reported as a derivative acquisition), for a total of 108,900 RSUs. These were granted at $0.00 (no cash purchase).
On the same date he disposed of 808 ordinary shares in an open-market sale at a weighted average price of $9.06, generating approximately $7,320. The sale was executed automatically to cover estimated withholding taxes upon RSU vesting.

Key Details

Transaction date(s): March 4, 2026; Form 4 filed March 6, 2026.
Sale price: weighted average $9.06 per share (range $9.00–$9.22). Proceeds ≈ $7,320.
Grants: 41,700 RSUs (A) and 67,200 RSUs (A, derivative). Reported acquisition price $0.00.
Ownership after transaction: not disclosed in the filing.
Notable footnotes:
- F1: RSUs granted under the 2014 Share Incentive Plan; each RSU converts to one ordinary share and vests in three equal annual installments beginning one year after grant.
- F2: The 808-share sale was an automatic sell-to-cover for tax withholding, not a discretionary trade by the reporting person.
- F3: Sale price is a weighted average; multiple executions between $9.00 and $9.22.
- F4: (Describes a stock option vesting schedule included in the filing; not an exercised-option transaction here.)
Filing timeliness: Form 4 was filed two days after the transactions; filing date consistent with usual reporting (no late-filing flag indicated).

Context

RSU grants are compensation awards that vest over time and are not an outright purchase; they represent a contingent right to shares subject to continued service.
The small sale was routine sell-to-cover tax withholding tied to vesting and should not be interpreted as a discretionary bearish signal.

Form 4

Period: 2026-03-04

Chief Medical Officer

Transactions

Award
Ordinary Shares
[F1]
2026-03-04+41,700→ 190,477 total
Sale
Ordinary Shares
[F2][F3]
2026-03-04$9.06/sh−808$7,320→ 189,669 total
Award
Stock Option (Right to Buy)
[F4]
2026-03-04+67,200→ 67,200 total
Exercise: $9.04Exp: 2036-03-04→ Ordinary Shares (67,200 underlying)

Footnotes (4)

[F1]Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest in equal annual installments of 1/3 each, beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such dates.
[F2]The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person.
[F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.22. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
[F4]The Stock Option vests 25% on the first anniversary of the date of grant, and 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates.

Signature

/s/ Christian Klemt, Attorney-in-Fact|2026-03-06

1 file